Thanks, Tom, for keeping us abreast of the latest research and conferences.
Interestingly, Raging Bull highlighted BCHE today on the site's opening page:
ragingbull.com
<<<Today's Biowatch spotlight is on BioChem Pharma (BCHE), a top-tier biotech organization with a very low profile. Ever hear of miracle AIDS drug 3TC, used in combination therapy with AZT and protease inhibitors to create the now-famous "AIDS cocktail"?...
...BioChem's next-generation AIDS drug is dOTC, which has shown strong efficacy in clinical studies to date. However, results from a study conducted with dOTC in primates showed unexpected toxic effects....
...On Monday, a federal advisory panel rejected Gilead Sciences' (GILD) anti-HIV adefovir dipivoxil pill for fighting resistant strains of the HIV virus that causes AIDS. The panel vote wasn't even close, 13-1 against recommending approval.>>>...
These drugs and their 'cocktails' have their perils. This is even MORE reason to develop an effective VACCINE!
Also noted:
...<<<BioChem was the company that developed 3TC, but many investors think it was co-marketer Glaxo Wellcome (GLX) who created the product...
...However, BioChem does not book 3TC sales, and only receives royalties in the vicinity of 10% to 15%, a terrible deal for BioChem. I guess BioChem didn't realize the potential of this product when it was in early clinical trials.>>>...
It seems Cel-Sci's management doesn't want the same fate!! Which, BTW, I consider a wise decision.
My best,
T. |
